Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLK1 | P53350 | 19/20 | 0.84 |
| ▸ | CYP2C9 | P11712 | 8/20 | 0.84 |
| ▸ | PLK3 | Q9H4B4 | 7/20 | 0.84 |
| ▸ | CYP3A4 | P08684 | 11/20 | 0.81 |
| ▸ | CDK2 | P24941 | 1/20 | 0.73 |
| ▸ | IKBKE | Q14164 | 1/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3575332 | 1.00 | PLK1 (0.84) | PLK1CYP2C9PLK3CYP3A4CDK2 | |
| SCHEMBL4839634 | 0.93 | PLK1 (0.89) | PLK1CYP2C9PLK3CYP3A4CDK2 | |
| SCHEMBL14029682 | 0.92 | PLK1 (0.81) | PLK1CYP2C9PLK3CYP3A4CDK2 | |
| SCHEMBL3151246 | 0.91 | PLK1 (0.80) | PLK1CYP2C9PLK3CYP3A4CDK2 | |
| SCHEMBL13573204 | 0.91 | PLK1 (1.00) | PLK1CYP2C9PLK3CYP3A4CDK2 | |
| SCHEMBL4404322 | 0.91 | PLK1 (1.00) | PLK1CYP2C9PLK3CYP3A4CDK2 | |
| SCHEMBL4413428 | 0.90 | PLK1 (0.87) | PLK1CYP2C9PLK3CYP3A4CDK2 | |
| SCHEMBL13451093 | 0.90 | PLK1 (1.00) | PLK1CYP2C9PLK3CYP3A4CDK2 | |
| SCHEMBL4405207 | 0.90 | PLK1 (0.79) | PLK1CYP2C9PLK3CYP3A4CDK2 | |
| SCHEMBL3154850 | 0.90 | PLK1 (1.00) | PLK1CYP2C9PLK3CYP3A4CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100056525-A1 | 5- AND 6- SUBSTITUTED BENZIMIDAZOLE THIOPHENE COMPOUNDS | SMITHKLINE BEECHAM CORPORATION | 2010-03-04 | — | — | US | disclosed |
| US-20100056525-A1 | 5- AND 6- SUBSTITUTED BENZIMIDAZOLE THIOPHENE COMPOUNDS | SMITHKLINE BEECHAM CORPORATION | 2010-03-04 | — | — | US | disclosed |
| WO-2008070354-A2 | 5- AND 6- SUBSTITUTED BENZIMIDAZOLE THIOPHENE COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-06-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100056525-A1 | 5- AND 6- SUBSTITUTED BENZIMIDAZOLE THIOPHENE COMPOUNDS | CYP3A5, CYP2B6, CYP3A4 | PLK1 836/4885CYP2C9 9/4885PLK3 1941/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.